1 BTC
=
- USD
Mersana Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Mersana Therapeutics, Inc. Common Stock
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Market Statistics
Trading Metrics
How to Buy MRSN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MRSN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesDay One Biopharmaceuticals (NASDAQ: DAWN) has successfully completed its acquisition of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition adds Emi-Le, a novel antibody-drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma, to Day One's clinical pipeline, expanding its presence in adult oncology while maintaining focus on rare cancers.
Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Alexander & Baldwin (acquisition by MW Group and Blackstone affiliates for $21.20/share), Udemy (acquisition by Coursera in all-stock deal at 0.800 shares per share), United Security Bancshares (acquisition by Community West Bancshares at $10.88/share), and Mersana Therapeutics (acquisition by Day One Biopharmaceuticals for $25/share plus CVR).
